Krishna Institute of Medical Sciences (KIMS) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 consolidated revenue reached INR 879 crore, up 26.8% YoY and 9.6% QoQ, with EBITDA at INR 200 crore, up 8.5% YoY but down 1.4% QoQ.

• PAT for Q1 FY26 was INR 85 crore, down from INR 95 crore YoY and INR 106 crore QoQ; EPS for Q1 FY26 was INR 1.96, a 9.2% decline YoY.

• ARPOB and ARPP grew 11.8% and 9.8% YoY, with IP and OP volumes up 15.3% and 19.3% YoY.

• Expansion continued with new units in Thane, Bangalore, Kerala, and Andhra Pradesh.

• Unaudited consolidated and standalone financial results for the quarter ended June 30, 2025, were reviewed and approved by the Board on August 6, 2025.

Financial highlights

• Consolidated revenue from operations for Q1 FY26 was INR 8,716 million, up 26.6% YoY and 9.4% QoQ.

• EBITDA margin dropped to 22.7% from 26.6% YoY and 25.3% QoQ.

• Consolidated net profit attributable to owners was INR 786 million, compared to INR 866 million in Q1 FY25.

• Net debt as of June 30, 2024, was INR 2,020 crore.

• Cash and cash equivalents stood at INR 70 crore as of Q1 FY26.

Outlook and guidance

• EBITDA margin guidance for FY26 is in the 22%-25% range.

• Losses from new units expected to neutralize within 12 months of full operations, especially in Bangalore and Kerala.

• Company-level ARPOB expected to rise to INR 50,000-55,000 as new units ramp up.

• Expansion plans include new hospitals and departments in Bangalore, Ongole, Anantapur, Kondapur, and Rajahmundry, with significant capex and phased openings from Q2 FY26 to Q4 FY27.